Polaris Group’s ADI‑PEG 20 Shows Promising Clinical Activity in NSCLC When Combined with Standard First Line Chemotherapy Regimen

SAN DIEGO, January 10, 2018 – Polaris Group announced today that the combination of its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) with the standard first-line chemotherapy cisplatin + pemetrexed doublet (PemCis) has shown promising clinical activity in an ongoing phase 1 study cohort of non-squamous non-small cell lung carcinoma (NSCLC) patients. The results will be presented by Dr. Peter Szlosarek from Barts Cancer Institute, London, at the fifth AACR-IASLC International Joint Conference in San Diego.

Twenty-one chemo-naïve NSCLC patients were enrolled in the single-arm, open label study to assess the safety and preliminary activity of ADI+PemCis. The treatment was well tolerated, and demonstrated robust tumor responses. Ten patients (47.6%) had a partial response, and 8 patients (38.1%) had stable disease for a disease control rate of 85.7%.

“We are excited to see that ADI+ PemCis demonstrated robust anti-tumor activity in the chemo-naïve NSCLC patients,” said John Bomalaski, M.D., Executive Vice President, Medical Affairs at Polaris Pharmaceuticals, Inc. “There have been many exciting developments for NSCLC treatment in the past few years, especially in the area of immunooncology. We are planning new clinical studies that would combine ADI‑PEG 20 with standard chemotherapy as well as immunooncology therapy to maximize treatment effect for cancer patients.”

About ADI-PEG 20

ADI‑PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI‑PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI‑PEG 20.

About Polaris Group

Polaris Group specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. In addition to the ADI-PEG 20 program, Polaris Group is developing other therapeutic agents, including a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.